Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
17 February 2022Regulatory Scandion Oncology – Year-end Report 2021 Download Presentation Webcast Workbook
18 February 2021Regulatory Scandion Oncology – Year-end Report 2020 Download Presentation Webcast Workbook
20 February 2020Regulatory Scandion Oncology – Year-end Report 2019 Download Presentation Webcast Workbook
21 February 2019Regulatory Scandion Oncology – Year-end Report 2018 Download Presentation Webcast Workbook
  1. Frontpage
  2. Press releases
  3. Year end report

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.